SCHEMBL1733738

SCHEMBL1733738

CCN(CC)c1nc(C(N)=O)cc(-c2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.70
KMO O15229 2/20 0.46
SCN9A Q15858 7/20 0.44
PARP1 P09874 2/20 0.44
XDH P47989 1/20 0.44
CRHR1 P34998 1/20 0.43
PIK3CD O00329 1/20 0.43
PIK3CA P42336 1/20 0.43
PIK3CG P48736 1/20 0.43
CTSK P43235 4/20 0.42
CTSS P25774 2/20 0.42
ALDH1A1 P00352 1/20 0.42
KCNH2 Q12809 2/20 0.42
CYP1A2 P05177 1/20 0.42
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734231 0.87 KDM4E (0.71) KDM4ESCN9AKCNH2
SCHEMBL1733619 0.85 KDM4E (0.75) KDM4EKMOSCN9A
SCHEMBL1734592 0.84 KDM4E (0.66) KDM4ESCN9AXDHCTSKCTSS
SCHEMBL1733513 0.83 KDM4E (0.77) KDM4EKMOPARP1XDHCTSK
SCHEMBL1733607 0.83 KDM4E (1.00) KDM4ESCN9AALDH1A1CYP1A2CYP2C9
SCHEMBL1733687 0.82 KDM4E (0.75) KDM4EKMOSCN9APARP1CTSK
SCHEMBL1735802 0.81 KDM4E (0.73) KDM4EPARP1ALDH1A1
SCHEMBL1734461 0.81 KDM4E (0.72) KDM4ESCN9APARP1ALDH1A1
SCHEMBL1734527 0.80 KDM4E (0.70) KDM4ESCN9AALDH1A1
SCHEMBL1734575 0.80 KDM4E (0.70) KDM4EALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885KMO 3927/4885SCN9A 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.